This review highlights MRD detection methods and implications for treatment in adult B-ALL, suggesting improved clinical outcomes.
Key Points
The aim is to evaluate current methods for measuring MRD in adult acute lymphoblastic leukemia, focusing on their clinical relevance and actionable guidelines.
Review of existing MRD detection techniques including NGS, MFC, and qPCR.
Synthesis of European and US expert panel recommendations on MRD management.
Discussion on the implications of MRD results for treatment decisions and transplant eligibility.
High-sensitivity NGS can detect MRD at levels as low as 10−6, redefining patient status.
Emerging strategies indicate early NGS-negativity may allow deferral of transplants in certain standard-risk patients.
There are significant interpretive challenges regarding low-level positivity and discrepancies between detection methods.